financetom
Business
financetom
/
Business
/
What's Going On With Ocugen (OCGN) Shares?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Ocugen (OCGN) Shares?
Mar 25, 2024 8:21 AM

Ocugen Inc ( OCGN ) shares are trading higher by 25.6% to $2.06 during Monday’s session. The stock is trading higher, potentially on upward momentum, after the Third Circuit Court of Appeals last week upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen ( OCGN ).

Additionally, Ocugen ( OCGN ) earlier this month announced that on March 15, the Board of Directors approved an amendment to Ocugen’s bylaws, reducing the quorum requirement for stockholder meetings from a majority to one third of the outstanding shares entitled to vote generally in the election of directors.

A lower quorum requirement can make it easier for the company to conduct business at stockholder meetings, as it requires fewer shareholders to be present for decisions to be made. This change might be seen as a move to streamline corporate governance processes and enhance flexibility, which could be viewed favorably by investors.

See Also: Cannabis Dispensaries Outnumber McDonald’s Across US: ‘It’s All About Location’

How To Buy OCGN Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Ocugen’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, Ocugen ( OCGN ) has a 52-week high of $2.08 and a 52-week low of $0.34.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boqii Shares Rise After $4.2 Million Registered Direct Offering
Boqii Shares Rise After $4.2 Million Registered Direct Offering
Nov 3, 2025
01:21 PM EST, 11/03/2025 (MT Newswires) -- Boqii ( BQ ) shares jumped 21.8% in recent trading Monday after the company announced a registered direct offering expected to raise $4.2 million in gross proceeds. Under the offering, Boqii ( BQ ) will sell 1.5 million class A shares or pre-funded warrants at $2.80 per share, with the warrants exercisable at...
TAYLOR FARMS ACQUIRES NATURES WAY FOODS
TAYLOR FARMS ACQUIRES NATURES WAY FOODS
Nov 3, 2025
Leading North American producer of salads to expand into United Kingdom SALINAS, Calif., Nov. 3, 2025 /PRNewswire/ -- Taylor Farms today announced the acquisition of Natures Way Foods, one of the United Kingdom's leading fresh prepared food manufacturers. Based in Chichester, England, Natures Way Foods employs 1,300 people and specializes in the supply of fresh, convenient food supporting retail and...
WellStar $62 Million Financing Shores Up Growth Capital Ahead of Expected 2026 IPO
WellStar $62 Million Financing Shores Up Growth Capital Ahead of Expected 2026 IPO
Nov 3, 2025
01:19 PM EST, 11/03/2025 (MT Newswires) -- WELL Health Technologies ( WHTCF ) announced a $62 million Series B financing and private round for Wellstar, led by institutional investors, Mawer, Edgepoint and Picton. Wellstar is the healthcare SaaS platform within WELL, last disclosed generating +$70 million sales (80-90% recurring), 25% adj. EBITDA margins and growing at +20%, Stifel Canada notes....
Why Is Rein Therapeutics Stock Trading Higher On Monday?
Why Is Rein Therapeutics Stock Trading Higher On Monday?
Nov 3, 2025
Rein Therapeutics ( RNTX ) stock is trading higher on Monday, with a session volume of 41.2 million compared to its average volume of 162.67 thousand, according to data from Benzinga Pro. What Happened: The U.S. Food and Drug Administration (FDA) on Monday lifted the full clinical hold on the company’s Phase 2 RENEW trial of LTI-03 in patients with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved